These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1277229)

  • 1. X-ray crystallographic studies of cyclophosphamide (NSC-26271) derivatives.
    Camerman A; Smith HW; Camerman N
    Cancer Treat Rep; 1976 Apr; 60(4):517-22. PubMed ID: 1277229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated cyclophosphamide anticancer drugs: molecular structures of cis- and trans-4-hydroperoxyisophosphamides.
    Camerman A; Smith HW; Camerman N
    J Med Chem; 1983 May; 26(5):679-83. PubMed ID: 6842507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The problem of oncostatic specificity of cyclophosphamide (NSC-26271): Studies on reactions that control the alkylating and cytotoxic activity.
    Hohorst HJ; Draeger U; Peter G; Voelcker G
    Cancer Treat Rep; 1976 Apr; 60(4):309-15. PubMed ID: 1277206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271).
    Lelieveld P; van Putten LM
    Cancer Treat Rep; 1976 Apr; 60(4):373-9. PubMed ID: 1064468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two stable Fenton oxidation products of cyclophosphamide (NSC-26271) as precursors of 4-hydroxycyclophosphamide (NSC-196562) under physiologic conditions.
    Benckhuysen C; van der Steen J; Spanjersberg EJ
    Cancer Treat Rep; 1976 Apr; 60(4):369-72. PubMed ID: 945125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of cyclophosphamide (NSC-26271) metabolites and related derivatives by field-desorption and electron-impact mass spectrometry.
    Przybylski M; Ringsdorf H; Voelcker G; Draeger U; Peter G; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):509-16. PubMed ID: 1277228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular structure of the K-region cis-dihydrodiol of 7,12-dimethylbenz[a]anthracene.
    Zacharias DE; Glusker JP; Harvey RG; Fu PP
    Cancer Res; 1977 Mar; 37(3):775-82. PubMed ID: 402208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The X-ray structure and absolute configuration of the anticancer drug (+)-4-ketocyclophosphamide.
    Gdaniec M; Adamiak DA; Misiura K
    Acta Biochim Pol; 1989; 36(3-4):205-13. PubMed ID: 2485997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on the metabolism of isopnosphamide (NSC-109724) in man.
    Norpoth K
    Cancer Treat Rep; 1976 Apr; 60(4):437-43. PubMed ID: 1277219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective.
    Friedman OM; Wodinsky I; Myles A
    Cancer Treat Rep; 1976 Apr; 60(4):337-46. PubMed ID: 1277209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structures of two isomeric bicyclic derivatives of 4-hydroperoxyisophosphamide.
    Camerman N; Fawcett JK; Camerman A
    J Med Chem; 1983 May; 26(5):683-6. PubMed ID: 6842508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of 4-hydroperoxy derivatives of ifosfamide and trofosfamide by direct ozonation and preliminary antitumor evaluation in vivo.
    Hohorst HJ; Peter G; Struck RF
    Cancer Res; 1976 Jul; 36(7 PT 1):2278-81. PubMed ID: 945124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deactivation of cyclophosphamide (NSC-26271) metabolites by sulfhydryl compounds.
    Draeger J; Peter G; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):355-9. PubMed ID: 1277211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivatives.
    Peter G; Wagner T; Hohorst HJ
    Cancer Treat Rep; 1976 Apr; 60(4):429-35. PubMed ID: 1277218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.
    Brock N
    Cancer Treat Rep; 1976 Apr; 60(4):301-8. PubMed ID: 1277205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular structure of (+/-)-7,8,9,10-tetrahydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene determined by x-ray crystallography.
    Neidle S; Subbiah A; Kuroda R; Cooper CS
    Cancer Res; 1982 Sep; 42(9):3766-8. PubMed ID: 7105042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemistry, metabolism, and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and its stereoisomer.
    Takamizawa A; Iwata T; Yamaguchi K; Shiratori O; Harada M
    Cancer Treat Rep; 1976 Apr; 60(4):361-8. PubMed ID: 1277212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclic phosphoramide mustard (NSC-69945) derivatives of amino acids and peptides.
    Szekerke M
    Cancer Treat Rep; 1976 Apr; 60(4):347-54. PubMed ID: 1277210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lanthanide complexes of the chiral hexaaza macrocycle and its meso-type isomer: solvent-controlled helicity inversion.
    Gregoliński J; Slepokura K; Lisowski J
    Inorg Chem; 2007 Sep; 46(19):7923-34. PubMed ID: 17705368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dopaminergic (4aR,10bS)-cis- and (4aS,10bS)-trans-octahydrobenzo[F]quinolines have similar pharmacophores.
    Froimowitz M; Deng Y; Jacob JN; Li N; Cody V
    Drug Des Discov; 1995 Aug; 13(1):73-81. PubMed ID: 8882902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.